NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients With Metastatic Castrate-resistant Prostate Cancer to Bone Treated With Either Docetaxel-based Chemotherapy or Androgen Receptor (AR)-Directed Therapies
The study will look at how repeatable the NaF PET scans are before treatment. Scans will
also be performed after standard chemotherapy or hormone-directed treatment. This will allow
evaluation of how the NaF PET scans change with the chemotherapy or hormone-directed
therapy. In addition, NaF PET scans will be compared with standard computed tomography (CT)
and bone scans, as well as prostate specific antigen (PSA). This information could be used
to develop better ways to measure prostate cancer bone lesions. In turn, this could be used
to better evaluate treatment effects of standard chemotherapy and other new drugs being
developed to treat prostate cancer.
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
The repeatability of NaF PET/CT imaging for evaluating bone metastases in patients with metastatic castrate-resistant prostate cancer.
NaF PET/CT scan will be performed within 7 days prior to starting docetaxel- chemotherapy or hormone-directed therapy (baseline #1). A portion of subjects (first 20 subjects at each site, 60 subjects total) will have a second NaF PET/CT scan performed (baseline #2) within 2-5 days of the initial scan to see if measurements repeated over a short period of time are similar.
Glenn Liu, MD
University of Wisconsin, Madison
United States: Institutional Review Board
|University of Wisconsin Carbone Cancer Center||Madison, Wisconsin 53792-5669|